New farnesyltransferase inhibitors in the phenothiazine series

被引：39

作者：

Belei, Dalila ^{[1
]}

Dumea, Carmen ^{[1
]}

Samson, Alexandrina ^{[1
]}

Farce, Amaury ^{[2
,3
]}

Dubois, Joelle ^{[4
]}

Bicu, Elena ^{[1
]}

Ghinet, Alina ^{[1
,2
,5
]}

机构：

[1] Alexandru Ioan Cuza Univ, Fac Chem, Dept Organ Chem, Iasi 700506, Romania

[2] Univ Lille Nord France, F-59000 Lille, France

[3] Inst Chim Pharmaceut Albert Lespagnol, EA GRIIOT, IFR114, F-59006 Lille, France

[4] Ctr Rech Gif, CNRS, Inst Chim Subst Nat, UPR2301, F-91198 Gif Sur Yvette, France

[5] UCLille, GRIIOT, Lab Pharmacochim, EA 4481, F-59046 Lille, France

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2012年 / 22卷 / 14期

关键词：

Farnesyltransferase inhibitor; Anticancer agent; Phenothiazine; Triazole; FARNESYL TRANSFERASE INHIBITORS; PROTEIN FARNESYLTRANSFERASE; RAS GENES; N-RAS; CANCER; ASSAY; CARCINOMAS; BMS-214662; PANCREAS; AGENTS;

D O I：

10.1016/j.bmcl.2012.06.007

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The biological screening of the chemical library of our Organic Chemistry Department, carried out on an automated fluorescence-based FTase assay, allowed us to discover that a phenothiazine derivative (1d) was an inhibitor of farnesyltransferase. Three new series of human farnesyltransferase inhibitors, based on a phenothiazine scaffold, were synthesized with protein farnesyltransferase inhibition potencies in the low micromolar range. Ester derivative 9d was the most active compound in these series. Four synthesized compounds were evaluated for their antiproliferative activity on a NCI-60 cancer cell line panel. The modest results obtained in this preliminary investigation showed that mixing the phenothiazine and the 1,2,3-triazole motif in the structure of a single compound can lead to new scaffolds in the field of farnesyltransferase inhibitors. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：4517 / 4522

页数：6

共 47 条

[21] Gritsenko A.N., 1958, UCHENYE ZAPISKI I FA, V1, P13
[22] Farnesyl transferase inhibitors as anticancer agents
Haluska, P
Dy, GK
Adjei, AA
[J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (13) : 1685 - 1700
[23] HRUBAN RH, 1993, AM J PATHOL, V143, P545
[24] Discovery of (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity
Hunt, JT
Ding, CZ
Batorsky, R
Bednarz, M
Bhide, R
Cho, Y
Chong, S
Chao, S
Gullo-Brown, J
Guo, P
Kim, SH
Lee, FYF
Leftheris, K
Miller, A
Mitt, T
Patel, M
Penhallow, BA
Ricca, C
Rose, WC
Schmidt, R
Slusarchyk, WA
Vite, G
Manne, V
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (20) : 3587 - 3595
[25] Photoinduced reductive repair of thymine glycol: Implications for excess electron transfer through DNA containing modified bases
Ito, Takeo
Kondo, Akiko
Terada, Satoru
Nishimoto, Sei-ichi
[J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (33) : 10934 - 10942
[26] DNA Hairpins Containing a Diaminostilbene Derivative as a Photoinduced Electron Donor for Probing the Effects of Single-Base Mismatches on Excess Electron Transfer in DNA
Ito, Takeo
Hayashi, Aiko
Kondo, Akiko
Uchida, Tsukasa
Tanabe, Kazuhito
Yamada, Hisatsugu
Nishimoto, Sei-ichi
[J]. ORGANIC LETTERS, 2009, 11 (04) : 927 - 930
[27] Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors
Khuri, FR
Glisson, BS
Kim, ES
Statkevich, P
Thall, PF
Meyers, ML
Herbst, RS
Munden, RF
Tendler, C
Zhu, YL
Bangert, S
Thompson, E
Lu, C
Wang, XM
Shin, DM
Kies, MS
Papadimitrakopoulou, V
Fossella, FV
Kirschmeier, P
Bishop, WR
Hong, WK
[J]. CLINICAL CANCER RESEARCH, 2004, 10 (09) : 2968 - 2976
[28] Lang G., 2002, PCT Int. Appl, Patent No. [WO 2,002,007,689 Al 20020131, 2002007689, WO 2002007689 A1]
[29] Lobell RB, 2002, MOL CANCER THER, V1, P747
[30] Loehr M., 2005, NEOPLASIA, V7, P17

← 1 2 3 4 5 →